GlassScriptPhysician profile
Andrea Ramirez
NPI 1093396244
$1,589.62
in general payments reported to CMS, 2019-2025
17 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.09 · 2023: $140 · 2024: $96.81 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $240.69 | 2025 | Qelbree |
| Ucb, INC. | $218.32 | 2025 | Briviact, Nayzilam, Fintepla |
| Tris Pharma INC | $205.98 | 2025 | Onyda Xr, Dyanavel Xr |
| Acadia Pharmaceuticals INC | $163.34 | 2025 | Daybue |
| Ironshore Pharmaceuticals INC. | $161.51 | 2022-2024 | Jornay Pm |
| Corium, LLC | $146.86 | 2022-2025 | Azstarys |
| Livanova USA, INC. | $131.37 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Noven Therapeutics, LLC | $61.32 | 2025 | Xelstrym |
| Otter Pharmaceuticals, LLC | $46.53 | 2025 | Sympazan |
| Collegium Pharmaceutical, INC. | $39.40 | 2025 | Jornay Pm |
| Neurelis, INC. | $34.73 | 2025 | Valtoco |
| Sk Life Science, INC. | $31.73 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $26.00 | 2023 | Exparel, Iovera, Zilretta |
| Cranial Technologies, INC | $25.30 | 2023 | Doc Band |
| Azurity Pharmaceuticals, INC. | $22.28 | 2025 | Triptodur |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.14 | 2024 | Vaxelis, Gardasil 9, Vaqta |
| Mirum Pharmaceuticals, INC. | $17.12 | 2025 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.